The Latest Cardiac and Vascular News
Latest data from the SANTORINI disease registry show that the cardiovascular (CV) risk of hypercholesterolaemia patients was underestimated considerably in the clinical setting.1,2,3 SANTORINI data show that nearly 80% of patients who are at high-risk or very high-risk of CV […]
Cardiovascular disease (CVD), a leading cause of death and disability worldwide, involves structural and functional changes in the heart Local sterile inflammation by the innate immune system results in a signalling cascade, particularly activation of NLRP3 NLRP3 activation, along with […]
Commencement of regulatory pathway for U.S. market approval OXFORD, England, Jan. 11, 2022 (GLOBE NEWSWIRE) — GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the filing of its Pre-Submission for Cardio inCode-SCORE with the […]
New editorial published in the Journal of the American College of Cardiology compares cardiovascular disease prevention treatments MANHASSET, N.Y.–(BUSINESS WIRE)–Patients most likely to benefit from intensive systolic blood pressure treatment (SBP) versus standard treatment to reduce cardiovascular disease (CVD) may […]
BETonMACE Results Show 57% Hazard Reduction in Primary MACE for Patients on Apabetalone and New Oral Anti-Diabetic Treatments CALGARY, Alberta, Jan. 13, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce today additional […]
Basel, February 25, 2019 – Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy. […]
BEVERLY HILLS, Calif., Jan. 29, 2019 /PRNewswire/ — Without new treatment options and greater utilization of current cholesterol lowering therapies, the mortality rate from cardiovascular disease (CVD) could increase 62 percent by 2040, according to a study published in the January issue of Clinical Cardiology. While deaths due to CVD have […]
by Ken Dropiewski, Principal Consultant – McDermott &Bull Executive Search Executive Summary: This white paper discussion centers on ways in which three distinct branches of healthcare are currently being impacted by the introduction or use of artificial intelligence (AI). I’ll take […]
CAMBRIDGE, England–(BUSINESS WIRE)–PlaqueTec Ltd. has relocated its existing coronary plasma bank from Royal Papworth Hospital to the communal laboratory facility within the Babraham Research Campus in Cambridge. The company has also expanded its headquarters and device development facilities, which are now […]
CALGARY, Alberta, Jan. 11, 2018 (GLOBE NEWSWIRE) — Resverlogix Corporation (“Resverlogix” or the “Company”) (TSX:RVX) and the Resverlogix BETonMACE Clinical Steering Committee (CSC), represented by Professor Kausik Ray (Chair), are pleased to announce the FDA acceptance of the Company’s Phase 3 BETonMACE trial Protocol […]
